Literature DB >> 28867483

Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening.

Wei Yang1, Søren Berg Padkjær2, Jishu Wang3, Zhe Sun3, Bing Shan3, Li Yang3, Haibin Chen3, Lishan Kang3, Dennis Madsen2, Xun Li3, Chenxi Shen3, Bingke Yu3, Haisun Zhu3, Tzu-Yuan Chao3, Zhuoxiao Cao3, Dapeng Li3, Wei Liu3, Yanping Du3, Jinjing Xu3, Dongxia Hao3, Fengting Xu3, Lujia Peng3, Tengkun Li3, Lin Wang3, Lin Li3, Haimei Xing3, Di Liu3, Zibing Liu3, Zhishuang Guan3, Wan Wang3, Hong Cheng3, Henrik Østergaard2, Chihchuan Chang3, Zhiru Yang3, Esper Boel2, Jing Su3.   

Abstract

Interactions between protein ligands and receptors play crucial roles in cell-cell signalling. Most of the human cell surface receptors have been identified in the post-Human Genome Project era but many of their corresponding ligands remain unknown. To facilitate the pairing of orphan receptors, 2762 sequences encoding all human single-pass transmembrane proteins were selected for inclusion into a mammalian-cell expression library. This expression library, consisting of all the individual extracellular domains (ECDs), was constructed as a Fab fusion for each protein. In this format, individual ECD can be produced as a soluble protein or displayed on cell surface, depending on the applied heavy-chain Fab configuration. The unique design of the Fab fusion concept used in the library led to not only superior success rate of protein production, but also versatile applications in various high-throughput screening paradigms including protein-protein binding assays as well as cell binding assays, which were not possible for any other existing expression libraries. The protein library was screened against human coagulation factor VIIa (FVIIa), an approved therapeutic for the treatment of hemophilia, for binding partners by AlphaScreen and ForteBio assays. Two previously known physiological ligands of FVIIa, tissue factor (TF) and endothelial protein C receptor (EPCR) were identified by both assays. The cell surface displayed library was screened against V-domain Ig suppressor of T-cell activation (VISTA), an important immune-checkpoint regulator. Immunoglobulin superfamily member 11 (IgSF11), a potential target for cancer immunotherapy, was identified as a new and previously undescribed binding partner for VISTA. The specificity of the binding was confirmed and validated by both fluorescence-activated cell sorting (FACS) and surface plasmon resonance (SPR) assays in different experimental setups.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Expression library; Fab; High-throughput screening; IgSF11; VISTA

Mesh:

Substances:

Year:  2017        PMID: 28867483     DOI: 10.1016/j.jbiotec.2017.08.023

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  14 in total

1.  IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95.

Authors:  Hyunsoo Kim; Noriko Takegahara; Matthew C Walsh; Sarah A Middleton; Jiyeon Yu; Jumpei Shirakawa; Jun Ueda; Yoshitaka Fujihara; Masahito Ikawa; Masaru Ishii; Junhyong Kim; Yongwon Choi
Journal:  Bone Res       Date:  2020-02-10       Impact factor: 13.567

2.  VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses.

Authors:  Aaron Prodeus; Aws Abdul-Wahid; Amanda Sparkes; Nicholas W Fischer; Marzena Cydzik; Nicholas Chiang; Mays Alwash; Alessandra Ferzoco; Nathalie Vacaresse; Michael Julius; Reginald M Gorczysnki; Jean Gariépy
Journal:  JCI Insight       Date:  2017-09-21

Review 3.  IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy.

Authors:  Xi-Yang Tang; Yan-Lu Xiong; Xian-Gui Shi; Ya-Bo Zhao; An-Ping Shi; Kai-Fu Zheng; Yu-Jian Liu; Tao Jiang; Nan Ma; Jin-Bo Zhao
Journal:  Biomark Res       Date:  2022-07-13

Review 4.  The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.

Authors:  Wenwen Xu; TạMinh Hiếu; Subramaniam Malarkannan; Li Wang
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

5.  VSIG-3 as a ligand of VISTA inhibits human T-cell function.

Authors:  Jinghua Wang; Guoping Wu; Brian Manick; Vida Hernandez; Mark Renelt; Christian Erickson; Joanna Guan; Ravinder Singh; Simone Rollins; Alicia Solorz; Ming Bi; Jun Li; David Grabowski; Janette Dirkx; Camrin Tracy; Thomas Stuart; Chad Ellinghuysen; Daniel Desmond; Craig Foster; Vassilios Kalabokis
Journal:  Immunology       Date:  2018-10-10       Impact factor: 7.397

6.  The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis.

Authors:  Amina Ghouzlani; Soumaya Rafii; Mehdi Karkouri; Abdelhakim Lakhdar; Abdallah Badou
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

Review 7.  Secretome-Based Screening in Target Discovery.

Authors:  Mei Ding; Hanna Tegel; Åsa Sivertsson; Sophia Hober; Arjan Snijder; Mats Ormö; Per-Erik Strömstedt; Rick Davies; Lovisa Holmberg Schiavone
Journal:  SLAS Discov       Date:  2020-05-19       Impact factor: 3.341

Review 8.  The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases.

Authors:  José M Carballido; Camille Regairaz; Celine Rauld; Layla Raad; Damien Picard; Michael Kammüller
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

9.  IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95.

Authors:  Hyunsoo Kim; Noriko Takegahara; Matthew C Walsh; Sarah A Middleton; Jiyeon Yu; Jumpei Shirakawa; Jun Ueda; Yoshitaka Fujihara; Masahito Ikawa; Masaru Ishii; Junhyong Kim; Yongwon Choi
Journal:  Bone Res       Date:  2020-02-10       Impact factor: 13.567

10.  An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.

Authors:  Nishant Mehta; Sainiteesh Maddineni; Ryan L Kelly; Robert B Lee; Sean A Hunter; John L Silberstein; R Andres Parra Sperberg; Caitlyn L Miller; Amanda Rabe; Louai Labanieh; Jennifer R Cochran
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.